Listen on the go
CORRECT!
Next question
touchRESPIRATORY touchRESPIRATORY
Sleep Related Breathing Disorders
Watch Time: 4 mins

John Harsh, CHEST 2022: Long term safety of FT218 in the treatment of narcolepsy

Share this Video
Copy Link
Published Online: Nov 8th 2022

Once-nightly sodium oxybate (FT218) is currently being investigated in the open label phase 3 study RESTORE (NCT04451668) for the treatment of narcolepsy. We caught up with Prof. John Harsh (University of Colorado Boulder, Boulder, CO, USA) to discuss the aims, design, inclusion criteria and interim findings of the RESTORE study.

The abstract ‘LONG-TERM SAFETY OF ONCE-NIGHTLY SODIUM OXYBATE: INTERIM ANALYSIS OF DATA FROM RESTORE.’ (Poster 2111) was presented at CHEST 2022, 16-19 October, 2022.

Questions

  1. ​​What challenges are associated with the use of sodium oxybate in the treatment of narcolepsy? (0:24)
  2. What is FT218? (1:20)
  3. What are the aims, design and inclusion criteria of the RESTORE study? (2:01)
  4. What have been the interim findings among people who switched from twice nightly sodium oxybate to FT218? (2:31)
  5. If approved, what will be the clinical impact of FT218? (3:18)

Disclosures: John Harsh has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the CHEST meeting 2022.

Related Videos In Sleep Related Breathing Disorders
Sleep Related Breathing Disorders
Developed by Touch
Margaret Pisani, CHEST 2022: Highlights and networking opportunities
Watch Time: 4 mins

CHEST 2022 took place between October 16-19 in Nashville, TN, we interviewed editorial board member Prof. Margaret Pisani (Yale School of Medicine. New Haven, CT, USA) around her personal congress highlights and the networking opportunities which were available on site. Questions What CHEST presentations had the greatest impact this year and what were your personal […]

Sleep Related Breathing Disorders
Developed by Touch
John Harsh, CHEST 2022: Long term safety of FT218 in the treatment of narcolepsy
Watch Time: 4 mins

Once-nightly sodium oxybate (FT218) is currently being investigated in the open label phase 3 study RESTORE (NCT04451668) for the treatment of narcolepsy. We caught up with Prof. John Harsh (University of Colorado Boulder, Boulder, CO, USA) to discuss the aims, design, inclusion criteria and interim findings of the RESTORE study. The abstract ‘LONG-TERM SAFETY OF […]

Sleep Related Breathing Disorders
Developed by Touch
Joerg Steier, ATS 2022: the Delphi Consensus Statements on Excessive Daytime Sleepiness in Obstructive Sleep Apnea
Watch Time: 6 mins

It was a pleasure to talk with Professor Joerg Steier (King’s College London, London, UK) around the development of the Delphi Consensus Statements on the diagnosis and management of excessive daytime sleepiness in obstructive sleep apnea and how these statements will help identify and address the unmet needs. The abstract ‘Development of Delphi Consensus Statements […]

Trending In Sleep Related Breathing Disorders:

Margaret Pisani, CHEST 2022: Highlights and networking opportunities
Sleep Related Breathing Disorders
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72